Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced a preliminary (unaudited) estimate of net product revenue from sales of OFIRMEV® (acetaminophen) injection ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE